Literature DB >> 17686053

Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity.

Livio Trentin1, Marta Miorin, Monica Facco, Ilenia Baesso, Samuela Carraro, Anna Cabrelle, Nilla Maschio, Michela Bortoli, Gianni Binotto, Francesco Piazza, Fausto Adami, Renato Zambello, Carlo Agostini, Gianpietro Semenzato.   

Abstract

Chemokines and their receptors play a pivotal role in the regulation of B-lymphocyte trafficking. This study was aimed at investigating the pattern of chemokine receptor expression, including CCR1 to CCR3, CCR5 to CCR7, CXCR1 to CXCR5, and the migration ability of multiple myeloma (MM) plasma cells (PC). PC were recovered from the bone marrow (BM) of 29 MM patients, extramedullary sites of 10 patients and the BM of five controls. Flow cytometry analysis showed that the receptors mainly expressed on malignant BM PC were represented by CXCR4 (70% of patients), CCR1 (25%), CCR2 (25%), CCR5 (17%) and CXCR3 (20%), while other receptors were commonly lacking. The analysis performed on extramedullary (peripheral blood and pleural effusion) malignant PC demonstrated that the most represented receptors were CXCR4 (100%), CCR2 (66%) and CXCR1 (60%). The migratory capability of malignant PC at resting conditions identified three groups of patients with different migration (low, intermediate and high). As CXCR4 was the relevant chemokine receptor expressed by MM PC, its ligand CXCL12 induced their migration. These data suggest that malignant PC from MM display different chemokine receptor profiles and that CXCR4 is fully functional and might play a role in the spreading of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686053     DOI: 10.1111/j.1365-2141.2007.06686.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia.

Authors:  Christina Arieta Kuksin; Gabriela Gonzalez-Perez; Lisa M Minter
Journal:  Blood       Date:  2015-02-03       Impact factor: 22.113

2.  CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.

Authors:  Crystal Johnson-Holiday; Rajesh Singh; Erica Johnson; Shailesh Singh; Cecil R Stockard; William E Grizzle; James W Lillard
Journal:  Int J Oncol       Date:  2011-02-23       Impact factor: 5.650

3.  In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.

Authors:  Xinxin Xu; Jiao Yang; Yu Tang; Junxia Li; Yan Zhu; Hua Lu; Xiaoming Fei
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  Variation in innate immunity genes and risk of multiple myeloma.

Authors:  Mark P Purdue; Qing Lan; Idan Menashe; Tongzhang Zheng; Yawei Zhang; Meredith Yeager; H Dean Hosgood; Shelia H Zahm; Stephen J Chanock; Nathaniel Rothman; Dalsu Baris
Journal:  Hematol Oncol       Date:  2011-03       Impact factor: 5.271

5.  Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.

Authors:  D Wang; Y Fløisand; C V Myklebust; S Bürgler; A Parente-Ribes; P O Hofgaard; B Bogen; K Taskén; G E Tjønnfjord; F Schjesvold; J Dalgaard; A Tveita; L A Munthe
Journal:  Leukemia       Date:  2017-02-24       Impact factor: 11.528

6.  Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.

Authors:  A Gilchrist; T D Gauntner; A Fazzini; K M Alley; D S Pyen; J Ahn; S J Ha; A Willett; S E Sansom; J L Yarfi; K A Bachovchin; M R Mazzoni; J R Merritt
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

7.  Cell Trafficking in Multiple Myeloma.

Authors:  Giada Bianchi; Shaji Kumar; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2012-02-21

8.  CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion.

Authors:  Yueguo Li; Jing Wu; Peng Zhang
Journal:  Tumour Biol       Date:  2015-10-26

9.  Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis.

Authors:  Gamal Badr; Eric A Lefevre; Mohamed Mohany
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

10.  Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.

Authors:  Anup Kasi Loknath Kumar; Christopher Dakhil; Megha Teeka Satyan; Nisreen Haideri
Journal:  J Med Case Rep       Date:  2014-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.